Back to search

University of Patras

Πρωτόκολλο μελέτης προσδιορισμού της αντιδραστικότητας των αιμοπεταλίων με τη συσκευή μέτρησης VerifyNow σε ασθενείς υπό αιμοκάθαρση: σύγκριση της διπλής δόσης κλοπιδογρέλης (150mg) έναντι πρασουγρέλης (10mg)

Abstract

dc:description

Objectives High on treatment platelet reactivity (HTPR) during clopidogrel administration is frequent in patients undergoing chronic maintenance hemodialysis (HD). The primary aim of the study was to determine the antiplatelet effects of prasugrel (10 mg/day) versus high-dose clopidogrel (150 mg/day) in HD patients who present HTPR (“High on-Treatment Platelet Reactivity”) under standard dose of clopidogrel (75 mg/day).Methods We performed a prospective, single-center, single-blinded, investigator-initiated, randomized, cross-over study to compare platelet inhibition by prasugrel 10 mg/day versus high-dose 150 mg/day clopidogrel in 21 chronic HD patients with HTPR. Platelet function was assessed by the VerifyNow assay and genotyping was performed for CYP2C19*2 carriage.Results-ConclusionsThe primary end point of platelet reactivity (PR, measured in PRU) was lower in patients receiving prasugrel (least squares estimates (LS) 156.6, 95% CI 132.2-181.1) compared with high dose clopidogrel (LS 279.9, 95% CI 255.4-304.3), p<0.001). The LS mean difference between the two treatments was -113.4 PRU (95% CI -152.9 to -73.8, p<0.001) and -163.8 PRU (95% CI -218.1 to -109.2, p<0.001) in non-carriers and carriers of at least one CYP2C19*2 allele, respectively. HTPR rates were lower for prasugrel than clopidogrel, in all patients (19% vs 85.7%%, p<0.001) and in non-carriers (25.7% vs 80%, p=0.003). All carriers continued to demonstrate HTPR on high clopidogrel, but none while on prasugrel. In HD patients exhibiting HTPR following standard clopidogrel treatment, prasugrel 10 mg/d is significantly more efficient than doubling the clopidogrel dosage, in achieving adequate platelet inhibition. Both effects seem not to be influenced by the presence of the loss-of-function CYP2C19*2 allele carriage.

Degree

thesis:*
Grantor dc:publisher
University of Patras
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Panagiotou, Angeliki
  • Παναγιώτου, Αγγελική

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/35539

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Panagiotou, Angeliki; Παναγιώτου, Αγγελική. Πρωτόκολλο μελέτης προσδιορισμού της αντιδραστικότητας των αιμοπεταλίων με τη συσκευή μέτρησης VerifyNow σε ασθενείς υπό αιμοκάθαρση: σύγκριση της διπλής δόσης κλοπιδογρέλης (150mg) έναντι πρασουγρέλης (10mg). University of Patras, 2013. http://hdl.handle.net/10442/hedi/35539